Sphere-9 Catheter and Affera Ablation System
Medtronic, Inc. · Decision date Oct 6, 2026
What did the FDA approve?
On 2026-10-06, FDA recorded an approval decision for P240013/S028, a Real-Time Process supplement to the Sphere-9 Catheter and Affera Ablation System from Medtronic, Inc. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename. The recorded scope is limited to modifications to the packaging and labeling of the Sphere-9 Catheter and a Predetermined Change Control Plan to extend device shelf life from 13 months to 25 months.
This action amends the existing PMA rather than approving the system anew. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation, in the cardiovascular specialty under product code QZI. The source record includes no supporting documents, so the specific labeling revisions, the content of the change control plan and any clinical data behind the shelf-life extension are not described here and remain unknown.
FDA approval order statement
Approval for modifications to the packaging and labeling of the Sphere-9 Catheter and a Predetermined Change Control Plan to extend the shelf life of the device from 13 months to 25 months.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 6, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240013/S028
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240013 · Original PMA
Sphere-9 Catheter and Affera Ablation System
P240013/S028 received
Application receipt date recorded by FDA.
P240013/S031 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S028 · FDA decision
Real-Time Process
P240013/S032 · Related supplement
Affera Sphere-9 Mapping and Ablation Catheter
Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Oct 24, 2024 | FDA | |
Sphere-9 Catheter and Affera Ablation SystemP240013/S031 | Medtronic, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P240013/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
